Guggenheim Starts Arcutis Biotherapeutics Inc. (ARQT) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ARQT Hot Sheet
Price: $32.07 +0.31%
Rating Summary:
9 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
9 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Guggenheim analyst Seamus Fernandez initiates coverage on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) with a Buy rating and a price target of $36.00.
For an analyst ratings summary and ratings history on Arcutis Biotherapeutics Inc. click here. For more ratings news on Arcutis Biotherapeutics Inc. click here.
Shares of Arcutis Biotherapeutics Inc. closed at $27.61 yesterday.
You May Also Be Interested In
- Arcutis adds former AbbVie CMO Rob Scott to its board
- Tigress Financial Partners Resumes Southwest (LUV) at Buy
- H.C. Wainwright Assumes Coherus Biosciences (CHRS) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
